Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Elsevier research partner Karin Verspoor nominated for Women in AI award

Posted on April 5th, 2022 by

Network

In recognition of her numerous research accomplishments, Professor Karin Verspoor is nominated for the prestigious Women in AI Award under the ‘AI in Innovation’ category. Certainly, the interdisciplinary work she has undertaken with Elsevier has chemists and pharmaceutical companies excited about the real-world impact of automating the extraction of chemical reaction information from patents.

(more…)

How publishing can help address diversity in STEM

Posted on March 30th, 2022 by

The issue of diversity in science, technology, engineering and mathematics is not a new topic, but it is one that needs to be continually addressed as these sectors endeavor to be more inclusive. And it is possible that publishing, an area that itself has work to do in diversity, could provide some metrics to help confront the diversity deficit.

(more…)

The power of similarities to accelerate antiviral development for COVID-19

Posted on January 11th, 2022 by

In April 2020, I wrote a blog post entitled “Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development,” where I described research areas leveraging genetic and phenotypic similarities between SARS-CoV-2 and other known viruses. In my quest to find relevant data, I used Reaxys Medicinal Chemistry to generate a list of substances that interact with enterovirus 3C proteases, a target showing striking similarities with the main proteases of SARS-CoV and SARS-CoV-2. A set of interesting derivatives using a cyanohydrin as an anchor group caught my attention.1 Interestingly, Pfizer used the cyano warhead a few months later to design their protease inhibitor (PF-07321332). Pfizer’s antiviral forms a complex structure with SARS-CoV-2 Mpro, demonstrating the efficacy of the cyano warhead to form a covalent bond with the cysteine residue at the active site.2

(more…)

AI-driven innovation in Life Sciences: Data Science & AI amplifies your innovative drug R&D capabilities

Posted on November 4th, 2021 by

If you work in Life Sciences & Health, you’re likely aware of what Data Science and AI can bring to the table when it comes to sparking innovation. However, if you are not Big Pharma, it’s the how that slows down most LSH companies and organizations. We believe that Elsevier’s road-tested data and semantic technologies can address the challenges of Life Science data.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 93